|Articles|April 14, 2011

Test- Blogging

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

BostonGene Expands AI-Driven Oncology Collaborations with New AstraZeneca Deal

ByAndy Studna, Senior Editor

January 7th 2026

© putilov_denis - © putilov_denis - stock.adobe.com

Securing Comparator Drugs in Competitive EU Markets: Challenges and Practical Solutions

BySyed Fazle Rob, RPh

January 7th 2026

ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership

ByAndy Studna, Senior Editor

January 7th 2026

Image Credit: © Justlight - stock.adobe.com

Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial

ByAndy Studna, Senior Editor

January 6th 2026

Building More Representative Cancer Trial Populations

ByShanthi Sivendran, MD, MSCR, MBA,Andy Studna, Senior Editor

January 6th 2026

Test- Blogging

Newsletter

Related Content

BostonGene Expands AI-Driven Oncology Collaborations with New AstraZeneca Deal

Securing Comparator Drugs in Competitive EU Markets: Challenges and Practical Solutions

ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership

Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial

Building More Representative Cancer Trial Populations

Trending on Applied Clinical Trials Online

Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial

Fresh Starts, Real Readiness: Turning Site Initiation into a Trial Success Multiplier

ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership

ACT Brief: Reframing Site Initiation Readiness, Operational Execution as Competitive Advantage, and a Historic Motion Sickness Approval

Building More Representative Cancer Trial Populations